TY  - JOUR
A1  - Esnault, Clara
A1  - Schrama, David
A1  - Houben, Roland
A1  - Guyétant, Serge
A1  - Desgranges, Audrey
A1  - Martin, Camille
A1  - Berthon, Patricia
A1  - Viaud-Massuard, Marie-Claude
A1  - Touzé, Antoine
A1  - Kervarrec, Thibault
A1  - Samimi, Mahtab
T1  - Antibody–drug conjugates as an emerging therapy in oncodermatology
JF  - Cancers
N2  - Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. In this regard, targeted therapies (e.g., kinase inhibitors) or immune checkpoint-blocking antibodies outperformed conventional chemotherapy, with proven benefit to survival. Nevertheless, primary and acquired resistances as well as adverse events remain limitations of these therapies. Therefore, ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.
KW  - antibody–drug conjugates
KW  - oncodermatology
KW  - melanoma
KW  - skin squamous cell carcinoma
KW  - cutaneous T-cell lymphoma and Merkel cell carcinoma
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262192
SN  - 2072-6694
VL  - 14
IS  - 3
ER  -